The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.
 
Antonio Llombart-Cussac
Stock and Other Ownership Interests - Initia-Research; MedSIR
Consulting or Advisory Role - Lilly O.; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Lilly O.; Merck Sharp & Dohme
Research Funding - Agendia; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Lilly O.; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Catherine Harper-Wynne
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly O.; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Novartis; Pfizer
 
Antonia Perello
No Relationships to Disclose
 
Audrey Hennequin
No Relationships to Disclose
 
Adela Fernandez
No Relationships to Disclose
 
Marco Colleoni
Research Funding - Roche (Inst)
 
Vicente Carañana
Travel, Accommodations, Expenses - AstraZeneca
 
Vanesa Quiroga
Consulting or Advisory Role - Roche
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - GlaxoSmithKline; Lilly O.; Roche
 
Jacques Medioni
Consulting or Advisory Role - Daiichi Sankyo Pharmaceutical; Gilead Sciences; Lilly O.; MSD; Pfizer
Travel, Accommodations, Expenses - Lilly O.; Pfizer; Seagen
 
Vega Iranzo
No Relationships to Disclose
 
Duncan Wheatley
Honoraria - Gilead/Forty Seven; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Novartis; pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Sonia Del Barco
Honoraria - Daiichi Sankyo Pharmaceutical; Lilly O.; Novartis; Seagen
Travel, Accommodations, Expenses - Roche
 
Antonio Anton
Honoraria - AstraZeneca/Daiichi Sankyo; Lilly O.; Seagen
Consulting or Advisory Role - Daiichi Sankyo Pharmaceutical; Gilead Sciences; Lilly O.; Seagen
Expert Testimony - Lilly O.; Pfizer
 
Erion Dobi
Travel, Accommodations, Expenses - Pfizer
 
Manuel Ruiz-Borrego
Honoraria - AstraZeneca/Daiichi Sankyo; Novartis; Pfizer
 
Daniel Alcalá-López
Employment - MedSIR
 
Jhudit Pérez-Escuredo
Employment - MedSIR
 
Miguel Sampayo-Cordero
Consulting or Advisory Role - MedSIR; Optimapharm
Speakers' Bureau - MedSIR; Optimapharm
Research Funding - MedSIR
Travel, Accommodations, Expenses - MedSIR; Optimapharm
 
José Manuel Pérez-García
Employment - MedSIR
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Pharmaceutical; Eisai; Gilead Sciences; Lilly O.; Roche; Seagen
Travel, Accommodations, Expenses - Roche
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche